transplantation. This study investigates the course of liver allografts from multiorgan donors enrolled in the randomized dopamine trial between 2004 and 2007 (clinicaltrials.gov identifier: NCT00115115). There were 264 hemodynamically stable DBDs who were randomly assigned to receive low-dose dopamine. Dopamine was infused at 4 μg/kg/minute for a median duration of 6.0 hours (interquartile range, 4.4-7.5 hours). We assessed the outcomes of 212 liver transplantations (LTs) performed at 32 European centers. Donors and recipients of both groups were very similar in baseline characteristics. Pretransplant laboratory Model for End-Stage Liver Disease score was not different in recipients of a dopamine-treated versus untreated graft (18 ± 8 versus 20 ± 8; P = 0.12). Mean cold ischemia time was 10.6 ± 2.9 versus 10.1 ± 2.8 hours (P = 0.24). No differences occurred in biopsy-proven rejection episodes (14.4% versus 15.7%; P = 0.85), requirement of hemofiltration (27.9% versus 31.5%; P = 0.65), the need for early retransplantation (5.8% versus 6.5%; P > 0.99), the incidence of primary nonfunction (7.7% versus 8.3%; P > 0.99), and in-hospital mortality (15.4% versus 14.8%; P > 0.99). Graft survival was 71.2% versus 73.2% and 59.6% versus 62.0% at 2 and 3 years (log-rank P = 0.71). Patient survival was 76.0% versus 78.7% and 65.4% versus 69.4% at 1 and 3 years (log-rank P = 0.50). In conclusion, donor pretreatment with dopamine has no short-term or longterm effects on outcome after LT. Therefore, low-dose dopamine pretreatment can safely be implemented as the standard of care in hemodynamically stable DBDs.
Success in solid organ transplantation demands optimized care of the donation after brain death (DBD) donor in the intensive care unit (ICU). Low-dose dopamine has emerged as a promising drug for donor intervention to limit brain death-and cold ischemiarelated injury of transplantable organs. Retrospective case-control and a large registry-based study in renal transplantation consistently found that donor pretreatment with low-dose dopamine was associated with reduced delayed graft function and superior longterm graft survival after kidney transplantation. (1, 2) In 2009, our multicenter randomized donor intervention
Original article | 1337 trial confirmed that dopamine administered to a stable DBD at 4 µg/kg/minute until procurement of the kidneys improved initial graft function after transplantation. (3) We have recently presented the 5-year follow-up of that trial, whose most intriguing finding was that a temporal relationship exists with exposure. Dopamine improved longterm kidney graft survival when infused longer than 7 hours. (4) Post hoc analysis of heart transplants from multiorgan donors included in the dopamine trial also suggested improvements of the early clinical course, which translated into a relevant 3-year survival benefit for recipients of a dopamine-treated heart. (5) These findings are supported by a recent retrospective cohort study in pediatric heart transplantation. (6) Accordingly, growing evidence on dopamine's major effects in kidney and heart transplantation may place low-dose dopamine on the top of agents to be routinely administered to the multiorgan donor as a standard of care, (7) as soon as dopamine's effect on the outcomes of liver grafts is clarified. The present study resting upon the database of the randomized dopamine trial focuses on multiorgan donors who also donated their livers for liver transplantation (LT). Our study evaluates short and midterm LT outcomes primarily under safety considerations based on donor assignment to pretreatment with low-dose dopamine.
Patients and Methods

stUDY Design, patients, anD MeasUreMents
The present study is embedded in the database of the randomized dopamine trial designed as a prospective donor intervention trial in adult kidney transplantation (clinicaltrials.gov identifier NCT00115115). Rationale, design, and execution of the renal dopamine trial have been described elsewhere. (3) After confirmation of brain death and after consent for organ donation, 264 DBDs were randomized between 2004 and 2007 to receive or not receive a standardized 4 µg/kg/ minute low-dose dopamine infusion until cross-clamping before the start of cold perfusion. Eligible DBDs were hemodynamically stable without vasopressor support, except norepinephrine was administered at a dose not exceeding 0.4 µg/kg/minute. All donors were monitored to meet target parameters of hemodynamic stability. (8) Circulatory adverse effects such as tachycardia (>120 beats/minute) and/or hypertension (blood pressure >160/90 mm Hg) resulted in dose reduction (2 µg/kg/minute) or premature termination of the dopamine infusion. Taking these precautions, no circulatory destabilization occurred that rendered the organs unsuitable for donation. Allocation of donor organs, including liver allografts, was centrally directed by Eurotransplant (ET) and obeyed current standards of organ sharing.
The trial protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and was a priori approved by the institutional review board of the Medical Faculty of Mannheim, Germany and by the Kidney Advisory Committee of the ET International Foundation, Leiden, the Netherlands. The protocol was made available for discussion by the Liver Advisory Committee of ET before the trial started enrollment of eligible donors. The committee had no objections because the intervention with low-dose dopamine (1) involved a fully approved drug; (2) to current guidelines for maintaining circulatory stability in DBDs (1) ; and (3) did not influence subsequent scheduling for surgical organ recovery. All patients on the waiting list for LT consented that their pseudonymized data could be used for scientific analyses.
To examine the outcomes after LT, we sent out standardized questionnaires to the 32 LT centers involved, after data collection of the renal trial was completed. Response rate was 100%. We collected the routine measurements of alanine aminotransferase (ALAT), bilirubin, gamma-glutamyltransferase (GGT), and international normalized ratio (INR) recorded on a daily basis within the first postoperative week. Serial assessments were quantified as areas under the curve (AUCs) and were used to assess immediate posttransplant hepatocellular function/injury. We also requested information on critical events occurring early after LT such as arterial thromboses; the need for hemodialysis/hemofiltration; frequency and severity of biopsy-proven acute rejection (BPAR) episodes; the occurrence of early allograft dysfunction (EAD), defined as the presence of 1 or more of the following postoperative laboratory analyses: bilirubin ≥ 10 mg/dL on day 7, INR ≥ 1.6 on day 7, or ALAT/aspartate aminotransferase (ASAT) ≥ 2000 U/L within the first 7 days posttransplant; and the requirement of early retransplantation, defined as retransplantation within 72 hours after liver engraftment. Primary nonfunction (PNF) of the liver graft, defined either as the need for early retransplantation or patient death within ≤ 72 hours after transplant, (9) and in-hospital mortality were also assessed. In addition, we recorded the occurrence of ischemic-type biliary lesions (ITBLs) and evaluated allograft and patient survival until 3 years after LT.
Unambiguous clinical endpoints such as early critical clinical events like in-hospital mortality, arterial thromboses, need for early retransplantation and PNF, and survival at 1 and 3 years were used as primary outcome measures to address safety. In addition, we also considered hepatocellular enzyme release during the first week, the incidences of EAD and of BPAR, the need for renal replacement therapy, and the occurrence of ITBL.
Information on medical recipient characteristics, including underlying liver disease, most recent pretransplant laboratory values (serum creatinine, bilirubin, and INR for calculations of the laboratory Model for EndStage Liver Disease [MELD] score), and data on transplant characteristics, such as split liver/repeat LTs and cold and warm ischemia periods, were provided by ET. Donor characteristics were obtained from the standard ET donor information forms. These included demographics, causes of brain death, laboratory values, hemodynamic parameters, concomitant medication in the ICU, kind of the cold preservation solution, and organ quality (eg, fatty liver, based on the liver surgeon's estimation upon organ recovery). Anonymity of donors and recipients was ensured by the use of pseudonymized ET code numbers for data collection.
statistical analYses
Quantitative variables are presented by mean value and standard deviation (SD), whereas median and interquartile range (IQR) are given for time durations (ie, infusion time). Quantitative data have been evaluated by a 2-sample t test or the Mann-Whitney U test, as appropriate for data distribution. Qualitative variables were compared using chi-square or 2-sided Fisher's exact test, when appropriate. Statistical significance was assumed when P was <0.05. Outcomes were primarily analyzed according to the original trial group assignment of the DBD and considered 212 liver allograft recipients including split and combined transplants regardless of protocol violations according to trial assignment on intention-to-treat. None of the recipients was excluded. We generated Kaplan-Meier curves for time-to-event data and used log-rank tests to compare survival between groups.
We also performed analyses "on study medication" to enhance sensitivity for addressing safety, and we used duration of the dopamine infusion-measured in hours-as an explanatory variable, which also considered the infusion times of 9 liver allografts whose donors were prematurely discontinued or had received dopamine erroneously after study assignment. Accordingly, 2 "dopamine-assigned" livers that never received it were included with 0 infusion time (Fig. 1) .
Multivariate Cox regression of all-cause graft failure and patient mortality was applied to control for other putative confounding influences. To this end, various donor-and recipient-related variables were added to the statistical model. These included donor and recipient age; sex; donor treatment with norepinephrine, desmopressin, and glucocorticoids in the ICU; the surgeon's judgment of a fatty liver graft; recipients' laboratory MELD scores; split livers and repeat transplants; and cold ischemia time. The forward selection technique has been applied in order to select variables to be included into the final model using a significance level of 0.05. Results are presented as hazard ratios (HRs),
Original article | 1339
with a 95% confidence interval (CI) for a 1-unit change in the variable. Statistical analyses were carried out with Stata (Stata Corp., College Station, TX) and SAS, version 9.3 (SAS Institute Inc., Cary, NC).
Results
stUDY FlOW anD patient cHaracteristics
Of 264 donors who fulfilled the inclusion criteria, 124 were assigned to dopamine treatment and 140 to controls. In total, 205 donors were scheduled for liver donation. Given a 100% rate of liver recovery, these donations resulted in a total of 212 liver engraftments in 32 European centers. Of these, 197 allografts were whole LTs and 15 were engrafted as split livers. In 15 instances, a combined transplantation was performed. Ninety-three livers assigned to dopamine were treated per protocol. Median infusion time was 6.0 hours (IQR, 4.4-7.5 hours). In the control group, only 1 protocol violation occurred because 1 donor received dopamine after the study assignment (Fig. 1) .
Donors assigned to dopamine treatment and controls were similar in demographics, causes of brain death, laboratory assessments, blood pressure and urine production, therapies in the ICU, kind of cold perfusion solutions, and organ quality assessments, particularly fatty livers, as reported by the surgeon upon organ procurement (Table 1) . The same applied for the recipients. Apart from a trend to a higher number of women in the dopamine arm (P = 0.07), there were no significant between-group differences in demographics, underlying liver diseases, pretransplant laboratory values including the laboratory MELD score, split LTs, ischemic time periods, and immunosuppressive medication after transplant (Table 2) .
earlY OUtcOMes aFter lt
Serial assessments of routine laboratory values used as early markers for graft function were quantified as mean AUCs. These were largely similar when comparing the study groups: ALAT-4018 ± 3902 versus 3300 ± 2879 U/L, P = 0.29; bilirubin-27.0 ± 18.4 versus 30.0 ± 23.5 mg/dL, P = 0.64; GGT-1408 ± 1042 versus 1492 ± 1180 U/L, P = 0.82; and INR-7.72 ± 1.50 versus 7.65 ± 1.45, P = 0.52 (dopamine versus no dopamine, respectively; see Fig. 2 ).
Critical events early after transplantation, including incidences of arterial thromboses (6 NOTE: Data are given as n "%" or mean ± SD. *Other includes insult, hypoxia, and tumor. † Rated by the surgeon by estimation upon organ procurement. Six livers were not rated in the dopamine treated and untreated group, respectively. Table 3 ).
graFt anD patient sUrvival Until 3 Years
Overall graft survival was 72.2% (95% CI, 65.6%-77.7%) at 1 year and 60.9% (95% CI, 53.9%-67.1%) at 3 years after LT regarding the entire study cohort. Overall patient survival was 77.4% (95% CI, 71.1%-82.4%) at 1 year and 67.5% (95% CI, 60.7%-73.3%) at 3 years posttransplant, respectively. Follow-up data were 100% complete. Three-year allograft and patient survival was similar in recipients of a dopamine-treated versus untreated liver graft (59.6% versus 62.0%, logrank P = 0.71; 65.4 versus 69.4%, log-rank P = 0.50; Table 3 ; Fig. 3A,B) .
Multivariate Cox regression on study medication excluded any inadvertent associations of dopamine infusion time with patient mortality (HR, 1.01; 95% CI, 0.95-1.07; P = 0.68) and with graft failure until 3 years after LT (Table 4) . Fifteen patients received a combined transplantation (Fig. 1) , and another 39 recipients had hepatocellular carcinoma (HCC) as the underlying disease. Particularly, these 2 subgroups of patients had a higher risk of mortality after 3 years, which was 60.0% (95% CI, 37.2%-83.5%) in recipients of a combined transplantation and 38.5% (95% CI, 25.3%-55.5%) in cancer patients. Therefore, we performed 2 additional sensitivity analyses excluding the aforementioned high-risk subgroups. Yet, the HRs remained largely unchanged: duration of the dopamine infusion administered to the DBD before organ procurement neither affected allograft failure in liver-only recipients (HR, 1.01; 95% CI, 0.96-1.07; P = 0.70), nor after further exclusion of recipients who had cancer (HR, 1.02; 95% CI, 0.95-1.10; P = 0.50).
In addition, we confined our analyses to whole organ LT by excluding both the aforementioned 15 
Discussion
This study supports that treatment of DBD patients with low-dose dopamine at a dose of 4 µg/kg/minute does not harm the liver allografts. Our principal findings are the following. First, immediate posttransplant hepatocellular injury, parameters of liver allograft synthesis, and bile production remained unanimously unaffected by the donors' assignment to dopamine pretreatment. Second, low-dose dopamine entailed no measurable effects on adverse/critical posttransplant events like early arterial thromboses, need for hemodialysis/hemofiltration, incidences of early retransplants, PNF, BPAR, and ITBL. Third, in-hospital mortality as well as graft and patient survival until 3 years after transplantation were similar in recipients of a treated versus untreated liver allograft. The latter observation is in line with a previous register-based cohort study of 755 LT recipients, which found no statistical association of graft survival and vasopressor use in the DBD, including dopamine. (1) Our data gain additional credence from the fact that overall 1-year allograft and patient survival was comparable to a retrospective analysis of 462 LTs performed in 7 German LT centers between 2006 and 2007. (10) Also, 1-and 3-year graft survival rates largely comply with a previous registry-based study of 5939 LTs between 2003 and 2007, which validated the Organ Procurement and Transplantation Network-derived donor risk index for allocation purposes in the ET database. (11) Thus, the overall outcome data of our study cohort are in the range of what can be expected in the ET region.
While pretreating the DBD with low-dose dopamine ameliorated the clinical course after kidney (1) (2) (3) (4) and heart transplantation (5,6) -why did dopamine not confer any protection to the liver allograft in our study? One possible reason is that our study was underpowered. We estimated that a sample size of approximately 2400 patients is required to detect a clinically meaningful survival advantage of 5% in favor of dopamine with a statistical power of 80%. Perhaps a more convincing causation derives from the understanding of dopamine's molecular mode of action. Under cold storage conditions, oxidative stress arises because the intracellular pool of free iron ions is enhanced. (12) We were able to show that dopamine decelerates the deleterious amplification loop of intracellular calcium accumulation (13, 14) and subsequent adenosine triphosphate (ATP) consumption that governs cell death under cold storage conditions by scavenging of reactive oxygen species. (13) The dihydroxy-catechol ring structure carries the active domain conferring antioxidant properties. (15) Effectiveness relies on dopamine's intracellular accumulation before the graft becomes exposed to cold preservation. (12, 13, 16) Maintenance of a sufficient intracellular concentration under steady-state conditions of the continuous dopamine infusion until cross-clamping is the prerequisite of dopamine's propensity to protect renal, endothelial cells, and cardiomyocytes. (12, 16, 17) This appears to be not feasible in livers because in Original article | 1343
hepatocytes the highly active catechol-o-methyltransferase (COMT) in its predominant soluble COMT isoform (18, 19) rapidly degrades intracellular dopamine via o-methylation of the phenolic hydroxyl groups. (20) Enzymatic degradation of the dihydoxy-catechol ring structure (21) -solely occurring in the liver under warm circulatory conditions before procurement-will abrogate dopamine's potential to protect the graft against cold-inflicted injury. Notably, under ex vivo cold storage conditions, when the activity of the degrading enzyme (soluble COMT) is down-regulated, dopamine is capable of conferring protection also to the liver allograft. Dopamine added as an ex vivo adjunct to the cold preservation solution in an experimental rat model decreased parenchymal and mitochondrial enzyme release, reduced histologic signs of tissue injury, doubled bile production, and restored the tissue pool of ATP upon rewarming. (22) However, these beneficial effects in a mere experimental setting are not yet transferable to an effective strategy in clinical LT. Recently, Sun et al. (23) raised concerns against dopamine as first-line medication for hemodynamic stabilization of the DBD. In rat hepatocytes, prolonged exposure to high-dose dopamine (72 hours of incubation with ≥10 µg/mL) induced a G 1 growth arrest in vitro. Using a rodent brain-death model, the infusion of ultra-high-dose dopamine (50 µg/kg/minute) hampered nuclear factor kappa B signaling in liver grafts after cold preservation, thereby down-regulating antiapoptotic regulators. The authors concluded that high-dose dopamine may impair hepatocyte function with the propensity to inflammation and apoptosis, despite its well-known positive effects on hepatic hemodynamics. By contrast, incubating rat hepatocytes with lower-dose dopamine (≤ 1 µg/mL) consistently exhibited beneficial effects. Hepatocyte viability was improved after 24 hours, and antiapoptotic proteins were enhanced after dopamine when applied at low doses only. (23) These findings underscore the unambiguous dose-and time-dependency of dopamine's effects in organ transplantation. (4) Accordingly, treating the unstable brain-dead multiorgan donor with high-dose dopamine (≥ 10 µg/kg/minute) for hemodynamic stabilization via adrenoreceptor activation was associated not only with a lower liver organ yield, (24) but also predisposes kidney allografts to ischemic lesions (25) and cardiac allografts to contraction band necrosis. (26) Therefore, high-dose dopamine exceeding 10 µg/ kg/minute is not recommended according to current guidelines on optimized donor management. (8, 27) Our study has several limitations. First, the randomized dopamine trial was not designed to explore graft outcomes after LT. Study endpoints reflecting the performance of the liver allograft in the recipients after transplant were not prespecified. Second, our study, which was undertaken to assess safety of the dopamine donor before treatment, does not fulfil the quality of a noninferiority trial under formal considerations because neither a quantitative hypothesis for sample size calculations nor a noninferiority margin was defined beforehand. However, we included a post hoc estimate of statistical power indicating that our safety analysis of 212 European LT recipients with a reported 1-year graft failure rate of approximately 30% (see Table 3 ) provides a power of 83.8% to detect a 15% difference in liver graft survival at 1 year after transplant at a 1-sided α of 0.05.
Third, in analogy to the renal trial, but in retrospect, we assessed early graft function by routine laboratory tests of hepatocyte integrity, frequencies of BPAR, and patient/graft survival. In addition, we retrospectively recorded incidences of critical events, such as arterial thromboses, ITBL, and the need for renal replacement therapy known to predict mortality after LT. (28) Hence, our study is a post hoc analysis nested in a randomized controlled clinical trial, which needs to be recognized with the usual reservations.
Fourth, our principal finding that donor dopamine is safe for LTs cannot be simply transferred to brain-dead donors who are hemodynamically unstable or suffer from greater physiologic derangements because these were excluded from the randomized dopamine trial.
A major strength of our study is its high internal validity. No recipient was lost to follow-up. The present study evaluates a multicenter transplant activity under real-life conditions, where transplant recipients were not exposed to protocol-mandated interventions. Although our study was strictly observational in the recipients, donor Original article | 1345 assignment to treatment followed a prospective, randomized trial design, which enhances the reliability of our findings beyond the potential of major selection bias.
In conclusion, this study demonstrates that the use of low-dose dopamine at 4 µg/kg/minute in hemodynamically stable donors is safe in LT, and therefore, its use as a standard of care is warranted (29) because it benefits other organs, kidneys, and hearts, without deleterious effects in liver allografts.
